Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients-Reference-Cited by-同舟云学术

Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients

Published:2020-05-29 Issue:5 Volume:15 Page:e0234058
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Ding Yuqin^ORCID,Ding Kaijing,Yang Hongjian,He Xiangming,Mo Wenju,Ding Xiaowen

Funder

Natural Science Foundation of Zhejiang Province

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference27 articles.

1. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel +/- darbepoetin alfa in primary breast cancer—results at the time of surgery;M Untch;Ann Oncol,2011

2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) [Internet]. Breast Cancer, Version 3.2019. 2019 [cited September 6, 2019]. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathological complete response of locally advanced triple-negative breast cancer: case report;Siberian journal of oncology;2024-09-10

2. Meta-Analysis of Different Surgical Methods for Breast Cancer Patients;International Journal of Pharmacology;2024-06-15

3. Retrospective Observational Study to Determine the Epidemiology and Treatment Patterns of Patients with Triple-Negative Breast Cancer;Cancers;2024-03-07

4. Systemic treatment in triple-negative breast cancer patients — standard and novel approaches;Oncology in Clinical Practice;2023-12-05

5. Efficacy of dose-dense versus standard neoadjuvant chemotherapy regimensin luminal HER2-negative breast cancer: Interim results of single-centre study;Medical alphabet;2023-12-04